ASH 2015 - Multiple Myeloma

Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM

Conference Correspondent - ASH 2015 - Multiple Myeloma

The randomized, placebo-controlled phase 3 PANORAMA 1 trial demonstrated that panobinostat, a potent pan-deacetylase inhibitor, in combination with bortezomib/dexamethasone (PAN/BTZ/Dex) resulted in significant prolongation of progression-free survival (PFS) of approximately 4 months compared with placebo plus bortezomib/dexamethasone (Pbo/BTZ/Dex) in patients [ Read More ]

Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM

Conference Correspondent - ASH 2015 - Multiple Myeloma

Ishida and colleagues reported interim results of a phase 2 trial that evaluated reduced- intensity bortezomib/melphalan/prednisolone (VMP) followed by lenalidomide/low-dose dexamethasone (Rd) consolidation therapy and lenalidomide maintenance therapy to improve outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). [ Read More ]

Subgroup Analysis Based on Cytogenetic Risk Status: Carfilzomib / Lenalidomide / Dexamethasone versus Lenalidomide / Dexamethasone (ASPIRE Study)

Conference Correspondent - ASH 2015 - Multiple Myeloma

Carfilzomib has shown encouraging activity in high-risk subset of patients with relapsed and refractory multiple myeloma (MM) with cytogenetic abnormalities.1 The phase 3 ASPIRE study demonstrated that carfilzomib/lenalidomide/dexamethasone (KRd) therapy resulted in significant prolongation of progression-free survival (PFS) compared with [ Read More ]

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

Conference Correspondent - ASH 2015 - Multiple Myeloma

Daratumumab is a human anti-CD38 monoclonal antibody that was recently approved as monotherapy for the treatment of heavily treated patients with relapsed and refractory multiple myeloma (RRMM).1 Ongoing studies are evaluating daratumumab as combination therapy with different backbone therapies, including [ Read More ]